Versameb, transforming (m)RNA therapeutics to cure hard-to-treat and/or prevalent diseases, is pleased to announce the appointments of Hernán Levett, Dr Lily Geidelberg, Paul Korner, MD,…
Our portfolio company, Cimeio Therapeutics, a biotechnology company that is reinventing cell therapy through its leadership in the emerging field of epitope shielding, and Prime…
How Swiss life sciences startups can compete globally In this biotech networking event, Johnson & Johnson Innovation shared their approach towards external innovation and their…
Bridge Biotherapeutics’ partnering strategy and growth by external innovation In this biotech networking event, two speakers from Bridge Biotherapeutics talked about the history of their…
Phialogics AG has announced the appointment of Prof. Dr. Erich Schlick as Chairman of its Board of Directors. Erich was introduced to Phialogics by BaseLaunch…
Our portfolio company, Phialogics - a preclinical stage company developing cell-type-specific immune checkpoint activators to prevent multi-organ failure in autoimmune diseases, closed a €600k pre-seed…
Engimmune Therapeutics, a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, has announced the appointment of Dr. Lars Nieba as Chief Executive Officer. Engimmune…
Alentis Therapeutics is a thriving clinical-stage biotech company in Basel, Switzerland, developing breakthrough treatments for organ fibrosis and CLDN1 positive tumors. The company, lead by…